



YOU ARE CORDIALLY INVITED TO ATTEND

Major Depressive Disorder: Current Challenges and the Role of Glutamate as a Treatment Target

Objectives:

- The history and usage of monoamine-based treatments in major depressive disorder (MDD)
- The normal functioning of the neurotransmitter glutamate in the brain
- The proposed role of glutamate dysfunction in psychiatric disorders, including MDD
- Glutamate modulation as a potential target for MDD

Presented By:

John Fenley, MD
Psychiatrist
Psychiatric Associates

Date:

Monday, February 24, 2025

Time:

6:00 PM Eastern Time
Meeting Duration: 60 minutes

Meeting Information:

Bogartz's
4705 Old Kingston Pike
Knoxville, TN 37919

To reserve your spot, please contact Lyn McConnell
at lmcconnell@axsome.com or (929) 884-2918

Please note that there are no certified continuing medical education credits approved for this program.

Axsome Therapeutics, Inc. is committed to the principles of the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals. As part of our commitment to that Code, we cannot pay for any costs incurred for travel or food of spouses or guests of any program participants, and any such spouses or guests may not attend any portion of a program's meeting or event. We appreciate your understanding in this regard.

Due to state regulations, a prescriber licensed in Minnesota may not receive meals that exceed a total of \$50 per calendar year and prescribers in Vermont may not receive any meals. Meals may be reportable based on various state and federal laws.

